Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00108_DB00242_nanopub.RA09u0eK1Y4dxR5qX0RhPrhVSQSSvX7uaMg2UqT6T2ukQ#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00108_DB00242 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00108_DB00242 label "DDI between Natalizumab and Cladribine - Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. [drugbank_resource:DB00108_DB00242]" assertion.
- drugbank_resource:DB00108_DB00242 identifier "drugbank_resource:DB00108_DB00242" assertion.
- drugbank_resource:DB00108_DB00242 title "DDI between Natalizumab and Cladribine - Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab." assertion.
- drugbank:DB00108 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB00242 assertion.
- drugbank:DB00242 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB00242 assertion.